Hikma Pharmaceuticals (LON:HIK) Earns Buy Rating from Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Financial Group in a research report issued to clients and investors on Friday, Marketbeat reports. They currently have a GBX 2,360 target price on the stock. Jefferies Financial Group’s price objective points to a potential upside of 49.18% from the stock’s previous close.

Several other equities analysts also recently issued reports on the company. Deutsche Bank Aktiengesellschaft reduced their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Berenberg Bank reduced their price target on Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating for the company in a research report on Thursday, October 16th. Finally, JPMorgan Chase & Co. decreased their price target on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating for the company in a research note on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of GBX 2,416.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock traded up GBX 60 during midday trading on Friday, reaching GBX 1,582. 1,155,675 shares of the stock traded hands, compared to its average volume of 1,297,659. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,522 and a fifty-two week high of GBX 2,360. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The firm has a market cap of £3.50 billion, a price-to-earnings ratio of 9.47, a PEG ratio of 2.38 and a beta of 0.41. The firm has a fifty day moving average price of GBX 1,734.94 and a two-hundred day moving average price of GBX 1,896.07.

Insiders Place Their Bets

In other news, insider Mazen Darwazah bought 315,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was acquired at an average price of GBX 1,601 per share, with a total value of £5,043,150. Also, insider Laura Balan Balan bought 3,500 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average cost of GBX 1,821 per share, for a total transaction of £63,735. Over the last ninety days, insiders have acquired 332,500 shares of company stock valued at $533,130,500. 17.77% of the stock is currently owned by corporate insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.